ATCC and InSphero have formed a strategic partnership that is set to redefine standards and introduce new paradigms in the rapidly evolving field of 3D cell–based oncology research.
By combining the power of ATCC's gold-standard, authenticated cell lines with InSphero's innovative, industry-leading 3D cell-based assay platforms, the scientific community will gain unprecedented access to assay-ready 3D tumor microtissues that will help accelerate oncology research at a global scale. This partnership will also provide an expansive and diverse portfolio of tumor models in easy-to-use and workflow-ready formats, ensuring researchers have access to enriched data sets that underpin better decision making in drug safety and efficacy.
Read the press release to learn more about the partnership.
Learn more about our oncology portfolio
To fight cancer, scientists need access to a wide variety of model systems to elucidate the mechanisms behind the growth and metastasis of each tumor type.
ATCC supports this critical need by providing a comprehensive portfolio of authenticated cell lines, advanced biological models, cancer panels, and patient-derived models that can be used in biomarker discovery, tumor biology studies, drug screening, immuno-oncology, and more. Explore our resources to see how we can support your oncology studies.
Learn more
